생백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Live Attenuated Vaccines Market size is expected to reach USD 58.57 Billion in 2034 from USD 23.50 Billion (2025) growing at a CAGR of 10.68% during 2026-2034.

The global live attenuated vaccines market is experiencing steady growth due to the increasing demand for effective immunization against infectious diseases. Live attenuated vaccines contain weakened forms of pathogens that stimulate a strong immune response without causing severe illness. These vaccines are widely used to prevent diseases such as measles, mumps, rubella, and chickenpox.

The market is driven by growing vaccination programs, rising awareness about disease prevention, and increased government support for immunization initiatives. Healthcare organizations around the world are focusing on improving vaccine accessibility to control the spread of infectious diseases. Technological advancements in vaccine development have also improved the safety and effectiveness of live attenuated vaccines.

In the future, the live attenuated vaccines market is expected to expand as global vaccination campaigns continue to increase. Research efforts aimed at developing vaccines for emerging infectious diseases will play a crucial role in market growth. Improvements in vaccine storage, distribution systems, and global healthcare infrastructure are also expected to support long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Bacterial Vaccine
• Viral Vaccine

By Development

• Tissue Culture
• Embryonated Eggs
• Live Animals

By Mode Of Administration

• Oral
• Injectable
• Intranasal

By Age Group

• Pediatric
• Adult

By Indication

• Tuberculosis
• Measles
• Rotavirus
• Yellow Fever
• Oral Polio
• Influenza
• Other Indications

By End-Use

• Hospitals (Public, Private)
• Specialty Clinics
• Other End-Users

COMPANIES PROFILED

• Abbott, Bharat Biotech International Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Haffkine Biopharmaceutical Corporation Limited, HBI, Merck Co, Novartis Pharmaceuticals Corporation, Sanofi, Serum Institute of India Ltd, Valneva SE, Zydus Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Bacterial Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Viral Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY DEVELOPMENT 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Development
• 5.2. Tissue Culture Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Embryonated Eggs Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Live Animals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Mode Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast Indication
• 8.2. Tuberculosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.5. Yellow Fever Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.6. Oral Polio Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.7. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.8. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY END-USE 2022-2034 (USD MN and Million Doses)

• 9.1. Market Analysis, Insights and Forecast End-use
• 9.2. Hospitals (Public, Private) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 9.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 9.4. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 10. GLOBAL LIVE ATTENUATED VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.2.1 By Vaccine Type
  • 10.2.2 By Development
  • 10.2.3 By Mode Of Administration
  • 10.2.4 By Age Group
  • 10.2.5 By Indication
  • 10.2.6 By End-use
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.3.1 By Vaccine Type
  • 10.3.2 By Development
  • 10.3.3 By Mode Of Administration
  • 10.3.4 By Age Group
  • 10.3.5 By Indication
  • 10.3.6 By End-use
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.4.1 By Vaccine Type
  • 10.4.2 By Development
  • 10.4.3 By Mode Of Administration
  • 10.4.4 By Age Group
  • 10.4.5 By Indication
  • 10.4.6 By End-use
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.5.1 By Vaccine Type
  • 10.5.2 By Development
  • 10.5.3 By Mode Of Administration
  • 10.5.4 By Age Group
  • 10.5.5 By Indication
  • 10.5.6 By End-use
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 10.6.1 By Vaccine Type
  • 10.6.2 By Development
  • 10.6.3 By Mode Of Administration
  • 10.6.4 By Age Group
  • 10.6.5 By Indication
  • 10.6.6 By End-use
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL LIVE ATTENUATED VACCINES INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Abbott
  • 12.2.2 Bharat Biotech International Limited
  • 12.2.3 Boehringer Ingelheim International GmbH
  • 12.2.4 GlaxoSmithKline Plc
  • 12.2.5 Haffkine Biopharmaceutical Corporation Limited
  • 12.2.6 HBI
  • 12.2.7 Merck & Co
  • 12.2.8 Novartis Pharmaceuticals Corporation
  • 12.2.9 Sanofi
  • 12.2.10 Serum Institute Of India Ltd
  • 12.2.11 Valneva SE
  • 12.2.12 Zydus Group